Clinical Trials Directory

Trials / Completed

CompletedNCT04616027

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT RENAL IMPAIRMENT

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Pfizer · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.

Conditions

Interventions

TypeNameDescription
DRUGPF-06882961 20 mgPF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1

Timeline

Start date
2021-01-13
Primary completion
2022-02-18
Completion
2022-02-18
First posted
2020-11-04
Last updated
2024-05-10
Results posted
2024-05-10

Locations

3 sites across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04616027. Inclusion in this directory is not an endorsement.